Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Reexamination Certificate
2007-06-05
2007-06-05
Rawlings, Stephen L. (Department: 1643)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
C424S178100, C424S183100, C424S133100, C424S134100, C424S135100, C424S138100, C424S155100, C530S350000, C530S387100, C530S387300, C530S387700, C530S388800, C530S391300, C530S391700
Reexamination Certificate
active
10226844
ABSTRACT:
The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.
REFERENCES:
patent: 5859253 (1999-01-01), Beckett et al.
patent: 6156321 (2000-12-01), Thorpe et al.
patent: 6458552 (2002-10-01), Fourie et al.
patent: 2003/0166562 (2003-09-01), Rothenberg et al.
patent: WO 97/40072 (1997-10-01), None
patent: WO 0109189 (2001-02-01), None
Chen et al. Mol. Cell. Proteomics. Apr. 2002; 1 (4): 304-13.
Liu et al. Cancer J. Sep.-Oct. 2001; 7 (5): 395-403.
Jiang et al. J. Biol. Chem. Feb. 11, 2005; 280 (6): 4656-62.
Rae et al. International Journal of Cancer. 2000; 88: 726-32.
De Plaen et al. Immunogenetics. 1994; 40: 360-9.
Skolnick et al. Trends in Biotechnology 2000; 18: 34-9.
Saijo et al. Cancer Sci. Oct. 2004; 95 (10): 772-6.
Kelland Eur. J. Cancer. Apr. 2004; 40 (6): 827-36.
Amour et al. FEBS Lett. Jul. 31, 2002; 524 (1-3): 154-8.
Lendeckel et al. (J Cancer Res Clin Oncol. Jan. 2005;131(1):41-8).
Ishikawa et al. (Clin Cancer Res. Dec. 15, 2004;10(24):8363-70)
Alitalo et al., “Oncogene Amplification in Tumor Cells”,Advances in Cancer Research, vol. 47, pp. 235-281 (1986).
Baselga et al., “HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic Implications”,Oncology, vol. 11 (3 Suppl. 2). pp. 43-48 (Mar. 1997).
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2Monoclonal Antibody in Patients with HER2
eu-Overexpressing Metastatic Breast Cancer”,J. Clin. Oncol., vol. 14, No. 3, pp. 737-744 (Mar. 1996).
Bergers, G. et al., “Extrinsic Regulators of Epithelial Tumor Progression: Metalloproteinases”,Current Opinion in Genetics and Development, vol. 10, pp. 120-127 (2000).
Bishop, J., “Molecular Themes in Oncogenesis”,Cell, vol. 64, No. 2, pp. 235-248 (Jan. 25, 1991).
Bodey, B. et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy”,Anticancer Research, vol. 20, pp. 2665-2676, (2000).
Brown, P., “Matrix Metalloproteinase Inhibitors in the Treatment of Cancer”,Medical Oncology, vol. 14, pp. 1-10 (1997).
Curti, B., “Physical Barriers to Drug Delivery in Tumors”,Critical Reviews in Hematology/Oncology, vol. 14, pp. 29-39 (1993).
DeNardo, G. et al., “Strategies for Developing Effective Radioimmunotherapy for Solid Tumors”,Clinical Caner Research, vol. 5, pp. 3219s-3223s (1999).
Gura, T., “Systems for Identifying Drugs are Often Faulty”,Science, vol. 278, pp. 1041-1042 (1997).
Higuchi et al., “MS2 (ADAM 8) A Myelomonolytic Cell Surface Antigen: Expression, Chromosomal Localization and Production of Truncated ADAM 8 Transgenic Mice”,Tissue Antigens, vol. 48, p. 423 (1996).
Hunter, T., “Cooperation Between Oncogenes”,Cell, vol. 64, No. 2, pp. 249-270 (Jan. 25, 1991).
Hynes et al., “The Biology of erbB-2
eu/HER-2 and Its Role in Cancer”,Biochimica et Biophysica Acta, vol. 1198, No. 2-3, pp. 165-184 (Dec. 30, 1994).
Jain. R., “Barriers to Drug Delivery in Solid Tumors”,Scientific American, vol. 271, pp. 58-65 (1994).
Kataoka et al., “Structure of Murine CD156 Gene, Characterization of Its Promoter, and Chromosomal Location”,Journal of Biological Chemistry, vol. 29, pp. 18209-18215 (1997).
Lewis, G. et al., “Differential Responses of Human Tumor Cell Lines to anti- p185HER2 Monoclonal Antibodies”,Cancer Immunology, Immunotherapy, vol. 37, pp. 255-263 (1993).
Ravdin et al., “The c-erbB-2 proto-oncogene as a Prognostic and Predictive Marker in Breast Cancer: A Paradigm for the Development of Other Macromolecular Markers—A Review”,Gene, vol. 159, No. 1, pp. 19-27 (Jun. 14, 1995).
Schluesener, H., “The Disintegrin Domain of ADAM 8 Enhances Protection Against Rat Experimental Autoimmune Encephalomyelitis, Neuritis and Uveitis by a Polyvalent Autoantigen Vaccine”,Journal of Neuroimmunology, vol. 87, pp. 197-202 (1998).
Schwab et al., “Amplification of Cellular Oncogenes: A Predictor of Clinical Outcome in Human Cancer”,Genes, Chromosomes&Cancer, vol. 1, No. 3, pp. 181-193 (Jan. 1990).
Slamon et al., “Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene”,Science, vol. 235, pp. 177-182 (Jan. 9, 1987).
Slamon et al., “Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer”,Science, vol. 244, pp. 707-712 (May 12, 1989).
Stancovski, I. et al., “Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to theERBB2 Receptor on Tumor Growth”,Proceedings of the National Academy of Science USA, vol. 88, pp. 8691-8695 (1991).
Vitetta, E. et al., “Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy”,Cancer Research, vol. 54, pp. 5301-5309 (1994).
Yamamoto et al., “ADAM Family Proteins in the Immune System”,Immunology Today, vol. 20, No. 6, pp. 278-284 (1999).
Yamamoto et al., “Human MS2 Antigen: Molecular Cloning, Primary Amino Acid Sequence, and Tissue Distribution”,Leukocyte Typing V: White Cell Differentiation Antigens, (Proceedings of the Fifth International Workshop and Conf.), Schlossman et al., Oxford Univ. Press, pp. 1091-1093 (1995).
Yoshida et al., “Molecular Cloning on cDNA Encoding MS2 Antigen, a Novel Cd Surface Antigen Strongly Expressed in Murine Monolytic Lineage”,International Immunology, vol. 2, pp. 585-591 (1990).
Yoshiyama et al., “CD156 (Human ADAM8): Expression, Primary Amino Acid Sequence, and Gene Location”,Genomics, vol. 41, pp. 56-62 (1997).
Bodary Sarah C.
Fisher Karen L.
Genentech Inc.
Merchant & Gould P.C.
Rawlings Stephen L.
LandOfFree
Compositions and methods for the treatment of tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3887634